Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symptoms 96% Improvement Relative Risk Viral load 95% Viral clearance 8% primary Chaccour et al. NCT04390022 Ivermectin RCT EARLY TREATMENT Is early treatment with ivermectin beneficial for COVID-19? Double-blind RCT 24 patients in Spain Improved viral load with ivermectin (p=0.01) Chaccour et al., EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720 Favors ivermectin Favors control

The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial

Chaccour et al., EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720 (date from earlier preprint), NCT04390022 (history)
Chaccour et al., The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with.., EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720 (date from earlier preprint), NCT04390022
Dec 2020   Source   PDF  
  All Studies   Meta
Tiny RCT for early treatment of mild COVID-19 in low risk patients, with 12 400mcg/kg single dose ivermectin patients and 12 control patients, showing significantly faster viral load reduction and symptom improvement with ivermectin. Average median viral load for gene E and gene N mid-viral recovery at day 7: Ivermectin: 1637, control: 30175 (supplementary appendix). NCT04390022 (history).
See also: [].
This is the 9th of 46 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000014.
This is the 25th of 97 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion).
risk of symptoms, 96.0% lower, OR 0.04, p < 0.05, treatment 12, control 12, logistic regression, chance of presenting any symptom, RR approximated with OR.
viral load, 94.6% lower, relative load 0.05, p < 0.01, treatment 12, control 12, day 7 mid-recovery, average of gene E and gene N, data in supplementary appendix.
risk of no viral clearance, 8.0% lower, RR 0.92, p = 1.00, treatment 12, control 12, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chaccour et al., 7 Dec 2020, Double Blind Randomized Controlled Trial, Spain, peer-reviewed, 23 authors, average treatment delay 1.0 days, dosage 400μg/kg single dose, trial NCT04390022 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
Carlos Chaccour, Aina Casellas, Andrés Blanco-Di Matteo, Iñigo Pineda, Alejandro Fernandez-Montero, Paula Ruiz-Castillo, Mary-Ann Richardson, Mariano Rodríguez-Mateos, Carlota Jordán-Iborra, Joe Brew, Francisco Carmona-Torre, Miriam Giráldez, Ester Laso, Juan C Gabaldón-Figueira, Carlota Dobaño, Gemma Moncunill, José R Yuste, Jose L Del Pozo, N Regina Rabinovich, Verena Schöning, Felix Hammann, Gabriel Reina, Belen Sadaba, Mirian Fernández-Alonso
EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720
Background: Ivermectin inhibits the replication of SARS-CoV-2 in vitro at concentrations not readily achievable with currently approved doses. There is limited evidence to support its clinical use in COVID-19 patients. We conducted a Pilot, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of a single dose of ivermectin reduce the transmission of SARS-CoV-2 when administered early after disease onset. Methods: Consecutive patients with non-severe COVID-19 and no risk factors for complicated disease attending the emergency room of the Clínica Universidad de Navarra between July 31, 2020 and September 11, 2020 were enrolled. All enrollments occurred within 72 h of onset of fever or cough. Patients were randomized 1:1 to receive ivermectin, 400 mcg/kg, single dose (n = 12) or placebo (n = 12). The primary outcome measure was the proportion of patients with detectable SARS-CoV-2 RNA by PCR from nasopharyngeal swab at day 7 post-treatment. The primary outcome was supported by determination of the viral load and infectivity of each sample. The differences between ivermectin and placebo were calculated using Fisher's exact test and presented as a relative risk ratio. This study is registered at NCT04390022. Findings: All patients recruited completed the trial (median age, 26 [IQR 19À36 in the ivermectin and 21À44 in the controls] years; 12 [50%] women; 100% had symptoms at recruitment, 70% reported headache, 62% reported fever, 50% reported general malaise and 25% reported cough). At day 7, there was no difference in the proportion of PCR positive patients (RR 0¢92, 95% CI: 0¢77À1¢09, p = 1¢0). The ivermectin group had non-statistically significant lower viral loads at day 4 (p = 0¢24 for gene E; p = 0¢18 for gene N) and day 7 (p = 0¢16 for gene E; p = 0¢18 for gene N) post treatment as well as lower IgG titers at day 21 post treatment (p = 0¢24). Patients in the ivermectin group recovered earlier from hyposmia/anosmia (76 vs 158 patient-days; p < 0.001). Interpretation: Among patients with non-severe COVID-19 and no risk factors for severe disease receiving a single 400 mcg/kg dose of ivermectin within 72 h of fever or cough onset there was no difference in the
treatment in the ivermectin group with differences increasing from 3-fold lower at day 4 (p = 0¢24 for gene E; p = 0¢18 for gene N) to around 18-fold lower at day 7 (p = 0¢16 for gene E; p = 0¢18 for gene N) (Fig. 2 and Table S1 ). A similar tendency remained for the viral load at days 14 and 21, with values from patients in the ivermectin group consistently lower for at least one of the genes, the difference was not statistically significant at any single point (Fig. 2 and Table S1 ). The values of cycle thresholds had a very similar behavior (Figure S1 ). Summary statistics for viral kinetics are provided in Table S2 . a Hours before dosing b The slightly higher median systolic blood pressure in the placebo group at baseline was not seen in subsequent study visits and was judged as non-clinically significant, see table S3 for the evolution of all vital signs throughout the study, *Reported or measured fever. IQR: interquartile range Author contributions Carlos Chaccour and Aina Casellas had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Conceptualization Supplementary materials Supplementary material associated with this article can be found in the online version at doi:10.1016/j.eclinm.2020.100720.
Ahmed, Karim, Ross, A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis
Arshad, Pertinez, Box, Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics, Clin Pharmacol Ther
Barrows, Campos, Powell, A screen of FDA-approved drugs for inhibitors of Zika virus infection, Cell Host Microbe
Benefield, Skrip, Clement, Althouse, Chang et al., SARS-CoV-2 viral load peaks prior to symptom onset: a systematic review and individualpooled analysis of coronavirus viral load from 66 studies, medRxiv
Bray, Rayner, Noel, Jans, Wagstaff, Ivermectin and COVID-19: a report in antiviral research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, Antiviral Res
Caly, Druce, Catton, Jans, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Cevik, Tate, Lloyd, Maraolo, Schafers et al., SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis, Lancet Microbe, doi:10.1016/S2666-5247(20)30172-5
Chaccour, Abizanda, Irigoyen-Barrio, Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats, Sci Rep
Chaccour, Brew, Garcia-Basteiro, Ivermectin and COVID-19: how a flawed database shaped the pandemic response of several Latin-American countries
Chaccour, Ruiz-Castillo, Richardson, The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to evaluate the potential of ivermectin to reduce COVID-19 transmission in low risk, non-severe COVID-19 patients in the first 48 h after symptoms onset: a structured summary of a study protocol for a randomized control pilot trial, Trials
Changeux J-P, Amoura, Rey, Miyara, A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications, C R Biol
Dahdouh, Perona, Romero-Gomez, Mingorance, Garcia-Rodriguez, Ct values from SARS-CoV-2 diagnostic PCR assays should not be used as direct estimates of viral load, J Infect
De M Enonville, Rosignoli, Soares, Topical treatment of rosacea with ivermectin inhibits gene expression of cathelicidin innate immune mediators, LL-37 and KLK5, in reconstructed and ex vivo skin models, Dermatol Ther (Heidelb)
De Melo, Lazarini, Larrous, Anti-COVID-19 efficacy of ivermectin in the golden hamster, bioRxiv
European_Medicines_Agency, EMA decision of 18
Fontanet, Cauchemez, COVID-19 herd immunity: where are we?, Nat Rev Immunol
Gombart, The vitamin D-antimicrobial peptide pathway and its role in protection against infection, Fut Microbiol
Gomez-Ambrosi, Silva, Galofre, Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity, Int J Obes (Lond)
Han, Singh, Robinson-Bostom, Vezeridis, Weinstock et al., MeTC7, a novel vitamin D receptor (VDR) antagonist, induces cytotoxicity in metastatic melanoma cell lines and inhibits importin-mediated VDR nuclear transport and signaling, J Am Acad Dermatol
He, Lau, Wu, Temporal dynamics in viral shedding and transmissibility of COVID-19, Nat Med
Hoffmann, Mosbauer, Hofmann-Winkler, Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2, Nature
Kahlenberg, Kaplan, Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease, J Immunol
Krolewiecki, Lifschitz, Moragas, Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label, doi:10.2139/ssrn.3714649
Lauer, Grantz, Bi, The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application, Ann Intern Med
Liu, Yan, Wan, Viral dynamics in mild and severe cases of COVID-19, Lancet Infect Dis
Marklund, Leach, Axelsson, Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders, PLoS One
Mastrangelo, Pezzullo, Burghgraeve, Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, J Antimicrob Chemother
Miyauchi, Michigami, Sakaguchi, Importin 4 is responsible for ligandindependent nuclear translocation of vitamin D receptor, J Biol Chem
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ICON study, Chest
Rhee, Kanjilal, Baker, Klompas, Duration of SARS-CoV-2 infectivity: when is it safe to discontinue isolation?, Clin Infect Dis, doi:10.1093/cid/ciaa1249/5896916
Rubin, Difficult to determine herd immunity threshold for COVID-19, JAMA
R€ Oltgen, Powell, Wirz, Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome, Sci Immunol
Schaller, Gonser, Belge, Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea, J Eur Acad Dermatol Venereol
Torabi, Mohammadbagheri, Dilmaghani, Proinflammatory cytokines in the olfactory mucosa result in COVID-19 induced anosmia, ACS Chem Neurosci
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin a/b-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J
Who, COVID-19 Weekly epidemiological update -15
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop